Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI - Ep. 230
Why It Matters
He highlights concrete examples of AI‑driven pipelines that have accelerated candidate selection and reduced development timelines, illustrating a broader industry shift toward data‑centric, scalable research.
Summary
The episode explores how Recursion, led by CEO Chris Gibson, leverages AI and machine learning to speed up drug discovery and cut costs in the biopharmaceutical sector. Gibson explains the company’s tech‑bio approach, using massive data sets and automated experiments to identify promising compounds faster than traditional methods. He highlights concrete examples of AI‑driven pipelines that have accelerated candidate selection and reduced development timelines, illustrating a broader industry shift toward data‑centric, scalable research.
Comments
Want to join the conversation?
Loading comments...